Compare Navan Inc. Class A Common Stock (NAVN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Neurocrine Biosciences Inc — how do they compare? Navan Inc. Class A Common Stock trades at $23.63 (market cap $6.01B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.4× Navan Inc. Class A Common Stock's market cap, and Navan Inc. Class A Common Stock is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.
| NAVN | NBIX | |
|---|---|---|
Market Cap | $6.01B | $14.36B |
Volume | 2,990,425 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $30.58 | $185.50 |
52-Week Low | $8.51 | $123.10 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $5.36B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
